Bionime Balance Sheet Health
Financial Health criteria checks 0/6
Bionime has a total shareholder equity of NT$1.9B and total debt of NT$2.9B, which brings its debt-to-equity ratio to 158.8%. Its total assets and total liabilities are NT$5.6B and NT$3.7B respectively.
Key information
158.8%
Debt to equity ratio
NT$2.94b
Debt
Interest coverage ratio | n/a |
Cash | NT$387.35m |
Equity | NT$1.85b |
Total liabilities | NT$3.70b |
Total assets | NT$5.55b |
Recent financial health updates
Recent updates
Bionime (TWSE:4737) Is Reducing Its Dividend To NT$2
Jul 22Bionime (TWSE:4737) Will Pay A Smaller Dividend Than Last Year
Jul 01These Return Metrics Don't Make Bionime (TPE:4737) Look Too Strong
Apr 29Looking For Steady Income For Your Dividend Portfolio? Is Bionime Corporation (TPE:4737) A Good Fit?
Mar 23Did You Participate In Any Of Bionime's (TPE:4737) Respectable 83% Return?
Mar 05Should You Use Bionime's (TPE:4737) Statutory Earnings To Analyse It?
Feb 15Bionime (TPE:4737) Has A Somewhat Strained Balance Sheet
Feb 01How Has Bionime (TPE:4737) Allocated Its Capital?
Jan 19A Closer Look At Bionime Corporation's (TPE:4737) Uninspiring ROE
Jan 06A Look At The Fair Value Of Bionime Corporation (TPE:4737)
Dec 22Bionime Corporation (TPE:4737) Investors Should Think About This Before Buying It For Its Dividend
Dec 09Bionime (TPE:4737) Has Compensated Shareholders With A Respectable 50% Return On Their Investment
Nov 24Financial Position Analysis
Short Term Liabilities: 4737's short term assets (NT$1.6B) do not cover its short term liabilities (NT$2.0B).
Long Term Liabilities: 4737's short term assets (NT$1.6B) do not cover its long term liabilities (NT$1.7B).
Debt to Equity History and Analysis
Debt Level: 4737's net debt to equity ratio (137.8%) is considered high.
Reducing Debt: 4737's debt to equity ratio has increased from 101.8% to 158.8% over the past 5 years.
Debt Coverage: 4737's debt is not well covered by operating cash flow (6.3%).
Interest Coverage: Insufficient data to determine if 4737's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/02/07 12:18 |
End of Day Share Price | 2025/02/07 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bionime Corporation is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Ryan Liu | IBTS Investment Consulting Co., Ltd. |
Zhennan Lee | Jih Sun Securities Investment Consulting Co., Ltd. |
Hsiu Chi Lin | Masterlink Securities Corp. |